Tenascin-C in cardiovascular remodeling: potential impact for diagnosis, prognosis estimation and targeted therapy

References

• Fuster V, Kelly BB. Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health. Editors Institute of Medicine (US) Committee on Preventing the Global Epidemic of Cardiovascular Disease: Meeting the Challenges in Developing Countries; Washington (DC): National Academies Press (US); 2010. The National Academies Collection: Reports funded by National Institutes of Health.
   Google Scholar
• Bowers SL, Banerjee I, Baudino TA. The extracellular matrix: at the center of it all. J Mol Cell Cardiol 2010; 48:474-82; PMID:19729019; http://dx.doi.org/10.1016/j.yjmcc.2009.08.024
   PubMedGoogle Scholar
• Midwood KS, Hussenet T, Langlois B, Orend G. Advances in tenascin-C biology. Cell Mol Life Sci: CMLS 2011; 68:3175-99; PMID:21818551; http://dx.doi.org/10.1007/s00018-011-0783-6
   PubMed Web of Science ®Google Scholar
• Borsi L, Balza E, Gaggero B, Allemanni G, Zardi L. The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH. J Biol Chem 1995; 270:6243-5; PMID:7534307; http://dx.doi.org/10.1074/jbc.270.11.6243
   PubMed Web of Science ®Google Scholar
• Jones PL, Jones FS. Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol: J Int Soc Matrix Biol 2000; 19:581-96; PMID:11102748; http://dx.doi.org/10.1016/S0945-053X(00)00106-2
   PubMed Web of Science ®Google Scholar
• Willems IE, Arends JW, Daemen MJ. Tenascin and fibronectin expression in healing human myocardial scars. J Pathol 1996; 179:321-5; PMID:8774490; http://dx.doi.org/10.1002/(SICI)1096-9896(199607)179:3%3c321::AID-PATH555%3e3.0.CO;2-8
   PubMedGoogle Scholar
• Franz M, Berndt A, Altendorf-Hofmann A, Fiedler N, Richter P, Schumm J, Fritzenwanger M, Figulla HR, Brehm BR. Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy. Eur J Heart Failure 2009; 11:1057-62; PMID:19815660; http://dx.doi.org/10.1093/eurjhf/hfp128
   PubMedGoogle Scholar
• Franz M, Brehm BR, Richter P, Gruen K, Neri D, Kosmehl H, Hekmat K, Renner A, Gummert J, Figulla HR, et al. Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies. J Mol Histol 2010; 41:39-50; PMID:20232238; http://dx.doi.org/10.1007/s10735-010-9260-z
   PubMedGoogle Scholar
• Imanaka-Yoshida K, Hiroe M, Nishikawa T, Ishiyama S, Shimojo T, Ohta Y, Sakakura T, Yoshida T. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest; J Tech Methods Pathol 2001; 81:1015-24; PMID:11454990; http://dx.doi.org/10.1038/labinvest.3780313
   PubMedGoogle Scholar
• Imanaka-Yoshida K, Hiroe M, Yasutomi Y, Toyozaki T, Tsuchiya T, Noda N, Maki T, Nishikawa T, Sakakura T, Yoshida T. Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol 2002; 197:388-94; PMID:12115886; http://dx.doi.org/10.1002/path.1131
   PubMed Web of Science ®Google Scholar
• Imanaka-Yoshida K. Tenascin-C in cardiovascular tissue remodeling: from development to inflammation and repair. Circ J: Off J Jpn Circ Soc 2012; 76:2513-20; PMID:23064399; http://dx.doi.org/10.1253/circj.CJ-12-1033
   PubMedGoogle Scholar
• Imanaka-Yoshida K, Yoshida T, Miyagawa-Tomita S. Tenascin-C in development and disease of blood vessels. Anat Rec 2014; 297:1747-57; PMID:25125186; http://dx.doi.org/10.1002/ar.22985
   PubMedGoogle Scholar
• Ihida-Stansbury K, McKean DM, Lane KB, Loyd JE, Wheeler LA, Morrell NW, Jones PL. Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2006; 291:L694-702; PMID:16782755; http://dx.doi.org/10.1152/ajplung.00119.2006
   PubMedGoogle Scholar
• Jones PL, Cowan KN, Rabinovitch M. Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. Am J Pathol 1997; 150:1349-60; PMID:9094991
   PubMed Web of Science ®Google Scholar
• Celik A, Kocyigit I, Calapkorur B, Korkmaz H, Doganay E, Elcik D, Ozdogru I. Tenascin-C may be a predictor of acute pulmonary thromboembolism. J Ather Thromb 2011; 18:487-93; PMID:21350305; http://dx.doi.org/10.5551/jat.7070
   PubMedGoogle Scholar
• Ballard VL, Sharma A, Duignan I, Holm JM, Chin A, Choi R, Hajjar KA, Wong SC, Edelberg JM. Vascular tenascin-C regulates cardiac endothelial phenotype and neovascularization. FASEB J: Off Pub Fed Am Soc Exp Biol 2006; 20:717-9; PMID:16461331
   PubMed Web of Science ®Google Scholar
• Kenji K, Hironori U, Hideya Y, Michinori I, Yasuhiko H, Nobuoki K. Tenascin-C is associated with coronary plaque instability in patients with acute coronary syndromes. Circ J: Off J Jpn Circ Soc 2004; 68:198-203; PMID:14993772; http://dx.doi.org/10.1253/circj.68.198
   PubMedGoogle Scholar
• Wallner K, Li C, Shah PK, Fishbein MC, Forrester JS, Kaul S, Sharifi BG. Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque. Circulation 1999; 99:1284-9; PMID:10077510; http://dx.doi.org/10.1161/01.CIR.99.10.1284
   PubMed Web of Science ®Google Scholar
• von Lukowicz T, Silacci M, Wyss MT, Trachsel E, Lohmann C, Buck A, Lüscher TF, Neri D, Matter CM. Human antibody against C domain of tenascin-C visualizes murine atherosclerotic plaques ex vivo. J Nucl Med: Off Pub, Soc Nucl Med 2007; 48:582-7; PMID:17401095; http://dx.doi.org/10.2967/jnumed.106.036046
   PubMedGoogle Scholar
• Pedretti M, Rancic Z, Soltermann A, Herzog BA, Schliemann C, Lachat M, Neri D, Kaufmann PA. Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: three clinical-grade fully human antibodies. Atherosclerosis 2010; 208:382-9; PMID:19699478; http://dx.doi.org/10.1016/j.atherosclerosis.2009.07.043
   PubMed Web of Science ®Google Scholar
• Celik A. The relationship between tenascin-C levels and the complexity of coronary lesion after myocardial infarction. J Ather Thromb 2011; 18:693-7; PMID:21512282; http://dx.doi.org/10.5551/jat.6577
   PubMedGoogle Scholar
• Sakamoto N, Hoshino Y, Misaka T, Mizukami H, Suzuki S, Sugimoto K, Yamaki T, Kunii H, Nakazato K, Suzuki H, et al. Serum tenascin-C level is associated with coronary plaque rupture in patients with acute coronary syndrome. Heart Ves 2014; 29:165-70; PMID:23532307; http://dx.doi.org/10.1007/s00380-013-0341-2
   PubMedGoogle Scholar
• Baldinger A, Brehm BR, Richter P, Bossert T, Gruen K, Hekmat K, Kosmehl H, Neri D, Figulla HR, Berndt A, et al. Comparative analysis of oncofetal fibronectin and tenascin-C expression in right atrial auricular and left ventricular human cardiac tissue from patients with coronary artery disease and aortic valve stenosis. Histochem Cell Biol 2011; 135:427-41; PMID:21479812; http://dx.doi.org/10.1007/s00418-011-0809-z
   PubMedGoogle Scholar
• Lauten A FH, Goebel B, Kretzschmar D, Hamadanchi A, Otto S, Ferrari M, Franz M. Effect of pressure unloading in severe aortic stenosis on LV hypertrophy and extracellular matrix remodelling - a clinical study in patients undergoing TAVI. Clin Res Cardiol 103, Suppl 1, April 2014; http://dx.doi.org/10.1007/s00392-014-1100-9
   PubMed Web of Science ®Google Scholar
• Sato A, Aonuma K, Imanaka-Yoshida K, Yoshida T, Isobe M, Kawase D, Kinoshita N, Yazaki Y, Hiroe M. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol 2006; 47:2319-25; PMID:16750702; http://dx.doi.org/10.1016/j.jacc.2006.03.033
   PubMed Web of Science ®Google Scholar
• Sato A, Hiroe M, Akiyama D, Hikita H, Nozato T, Hoshi T, Kimura T, Wang Z, Sakai S, Imanaka-Yoshida K, et al. Prognostic value of serum tenascin-C levels on long-term outcome after acute myocardial infarction. J Cardiac Failure 2012; 18:480-6; PMID:22633306; http://dx.doi.org/10.1016/j.cardfail.2012.02.009
   PubMed Web of Science ®Google Scholar
• Rybak JN, Trachsel E, Scheuermann J, Neri D. Ligand-based vascular targeting of disease. Chem Med Chem 2007; 2:22-40; PMID:17154429; http://dx.doi.org/10.1002/cmdc.200600181
   PubMedGoogle Scholar
• Minear MA, Crosslin DR, Sutton BS, Connelly JJ, Nelson SC, Gadson-Watson S, Wang T, Seo D, Vance JM, Sketch MH Jr, et al. Polymorphic variants in tenascin-C (TNC) are associated with atherosclerosis and coronary artery disease. Hum Genet 2011; 129:641-54; PMID:21298289; http://dx.doi.org/10.1007/s00439-011-0959-z
   PubMedGoogle Scholar
• Gabler U, Berndt A, Kosmehl H, Mandel U, Zardi L, Müller S, Stelzner A, Katenkamp D. Matrix remodelling in dilated cardiomyopathy entails the occurrence of oncofetal fibronectin molecular variants. Heart 1996; 75:358-62; PMID:8705761; http://dx.doi.org/10.1136/hrt.75.4.358
   PubMedGoogle Scholar
• Tamura A, Kusachi S, Nogami K, Yamanishi A, Kajikawa Y, Hirohata S, Tsuji T. Tenascin expression in endomyocardial biopsy specimens in patients with dilated cardiomyopathy: distribution along margin of fibrotic lesions. Heart 1996; 75:291-4; PMID:8800995; http://dx.doi.org/10.1136/hrt.75.3.291
   PubMedGoogle Scholar
• Aso N, Tamura A, Nasu M. Circulating tenascin-C levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2004; 94:1468-70; PMID:15566931; http://dx.doi.org/10.1016/j.amjcard.2004.07.156
   PubMed Web of Science ®Google Scholar
• Terasaki F, Okamoto H, Onishi K, Sato A, Shimomura H, Tsukada B, Imanaka-Yoshida K, Hiroe M, Yoshida T, Kitaura Y, et al. Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ J: Off J Jpn Circ Soc 2007; 71:327-30; PMID:17322629; http://dx.doi.org/10.1253/circj.71.327
   PubMed Web of Science ®Google Scholar
• Fujimoto N, Onishi K, Sato A, Terasaki F, Tsukada B, Nozato T, Yamada T, Imanaka-Yoshida K, Yoshida T, et al. Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure. J Cardiac Failure 2009; 15:898-905; PMID:19944367; http://dx.doi.org/10.1016/j.cardfail.2009.06.443
   PubMedGoogle Scholar
• Franz M, Berndt A, Neri D, Galler K, Grün K, Porrmann C, Reinbothe F, Mall G, Schlattmann P, Renner A, et al. Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, B(+) tenascin-C and ED-A(+) fibronectin in dilated cardiomyopathy: potential impact on disease progression and patients' prognosis. Int J Cardiol 2013; 168:5344-51; PMID:23998545; http://dx.doi.org/10.1016/j.ijcard.2013.08.005
   PubMedGoogle Scholar
• Sarli B, Topsakal R, Kaya EG, Akpek M, Lam YY, Kaya MG. Tenascin-C as predictor of left ventricular remodeling and mortality in patients with dilated cardiomyopathy. J Invest Med: Off Pub Am Fed Clin Res 2013; 61:728-32; PMID:23429699
   PubMedGoogle Scholar
• Morimoto S, Imanaka-Yoshida K, Hiramitsu S, Kato S, Ohtsuki M, Uemura A, Kato Y, Nishikawa T, Toyozaki T, Hishida H, et al. Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis. J Pathol 2005; 205:460-7; PMID:15685595; http://dx.doi.org/10.1002/path.1730
   PubMedGoogle Scholar
• Karatas Z, Baysal T, Alp H, Toker A. Serum tenascin-C: a novel biomarker for diagnosis and predicting prognosis of rheumatic carditis? J Trop Pediat 2013; 59:476-82; PMID:23868575; http://dx.doi.org/10.1093/tropej/fmt058
   PubMedGoogle Scholar
• Erer HB, Guvenc TS, Kemik AS, Yilmaz H, Kul S, Altay S, Oz D, Zeren G, Ekmekci A, Zencirci AE, et al. Assessment of tenascin-C levels in ventricular noncompaction/hypertrabeculation patients: a cross-sectional study. Echocardiography 2014; 31:203-8; PMID:23895622; http://dx.doi.org/10.1111/echo.12328
   PubMedGoogle Scholar
• Kitaoka H, Kubo T, Baba Y, Yamasaki N, Matsumura Y, Furuno T, Doi YL. Serum tenascin-C levels as a prognostic biomarker of heart failure events in patients with hypertrophic cardiomyopathy. J Cardiol 2012; 59:209-14; PMID:22218323; http://dx.doi.org/10.1016/j.jjcc.2011.11.008
   PubMed Web of Science ®Google Scholar
• Trescher K, Thometich B, Demyanets S, Kassal H, Sedivy R, Bittner R, Holzinger C, Podesser BK. Type A dissection and chronic dilatation: tenascin-C as a key factor in destabilization of the aortic wall. Interactive Cardiov Thoracic Surg 2013; 17:365-70; PMID:23656926; http://dx.doi.org/10.1093/icvts/ivt204
   PubMedGoogle Scholar
• Kimura T, Shiraishi K, Furusho A, Ito S, Hirakata S, Nishida N, Yoshimura K, Imanaka-Yoshida K, Yoshida T, Ikeda Y, et al. Tenascin C protects aorta from acute dissection in mice. Scientific reports 2014; 4:4051; PMID:24514259
   PubMedGoogle Scholar
• Franz M, Berndt A, Grun K, Kuethe F, Fritzenwanger M, Figulla HR, Jung C. Serum levels of tenascin-C variants in congestive heart failure patients: comparative analysis of ischemic, dilated, and hypertensive cardiomyopathy. Clin Lab 2014; 60:1007-13; PMID:25016707
   PubMed Web of Science ®Google Scholar
• Franz M, Grun K, Richter P, Brehm BR, Fritzenwanger M, Hekmat K, Neri D, Gummert J, Figulla HR, Kosmehl H, et al. Extra cellular matrix remodelling after heterotopic rat heart transplantation: gene expression profiling and involvement of ED-A+ fibronectin, alpha-smooth muscle actin and B+ tenascin-C in chronic cardiac allograft rejection. Histochem Cell Biol 2010; 134:503-17; PMID:20931338; http://dx.doi.org/10.1007/s00418-010-0750-6
   PubMed Web of Science ®Google Scholar
• Franz M, Matusiak-Bruckner M, Richter P, Grün K, Ziffels B, Neri D, Maschek H, Schulz U, Pfeil A, Jung C, et al. De novo expression of fetal ED-A(+) fibronectin and B (+) tenascin-C splicing variants in human cardiac allografts: potential impact for targeted therapy of rejection. J Mol Histol 2014; 45:519-32; PMID:24792713; http://dx.doi.org/10.1007/s10735-014-9573-4
   PubMedGoogle Scholar
• Casi G, Huguenin-Dezot N, Zuberbuhler K, Scheuermann J, Neri D. Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery. J Am Chem Soc 2012; 134:5887-92; PMID:22394212; http://dx.doi.org/10.1021/ja211589m
   PubMed Web of Science ®Google Scholar
• Franz M, Hilger I, Grun K, Kossatz S, Richter P, Petersen I, Jung C, Gummert J, Figulla HR, Kosmehl H, et al. Selective imaging of chronic cardiac rejection using a human antibody specific to the alternatively spliced EDA domain of fibronectin. J Heart Lung Transpl: Off Pub Int Soc Heart Transpl 2013; 32:641-50; PMID:23701854; http://dx.doi.org/10.1016/j.healun.2013.04.003
   PubMedGoogle Scholar